US Patent Covering Gene Therapy Drug Candidates for Treatment of Osteoarthritis Issued [ 07 Jun 2019 ]

The U.S. Patent and Trademark Office (USPTO) grants a patent for FX201 (GeneQuine’s former human drug candidate GQ-203, acquired by Flexion Therapeutics, Inc.) and veterinary analogs for treatment of osteoarthritis.

More


GeneQuine Opens New Research and Development Site and Receives Grant [ 01 Apr 2019 ]

GeneQuine opens up a new research and development site in the greater Berlin area (state of Brandenburg, Germany) and receives a local government grant (GRW program) to support establishing the site.

More


GeneQuine on Expert Panel Discussion at Merck’s Advance Biotech Grant Program Award Ceremony, 31 January 2019, Darmstadt [ 29 Jan 2019 ]

As a previous winner of Mercks’s European Emerging Biotech Grant Program, GeneQuine’s CEO Kilian Guse will hold an introductory speech on how the grant accelerated GeneQuine's development of a novel gene therapy platform and supported the lead program in osteoarthritis.

More